GlassScriptPhysician profile
Antonio Cubano
NPI 1881895951
$5,671.17
in general payments reported to CMS, 2019-2025
31 companies · $1,355 in 2025
The $1,355 reported for 2025 was more than what 89% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,248 · 2020: $816 · 2021: $683 · 2022: $48.47 · 2023: $412 · 2024: $1,109 · 2025: $1,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,821 · Education: $54.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,820.91 |
| Education | $54.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $1,223.77 | 2019-2024 | Trintellix |
| Otsuka America Pharmaceutical, INC. | $698.65 | 2019-2025 | Rexulti |
| Janssen Pharmaceuticals, INC | $341.81 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $325.51 | 2020-2025 | Caplyta |
| Lundbeck LLC | $312.42 | 2019-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $311.32 | 2021-2025 | Qelbree, Qelbree |
| Abbvie INC. | $310.86 | 2021-2025 | Vraylar |
| Neurocrine Biosciences, INC. | $269.42 | 2019-2025 | Ingrezza |
| Teva Pharmaceuticals USA, INC. | $255.77 | 2020-2025 | Austedo Xr, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $247.11 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $214.34 | 2024-2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $183.62 | 2019-2024 | Jornay Pm |
| Axsome Therapeutics, INC. | $135.81 | 2025 | Auvelity |
| Neos Therapeutics, LP | $134.83 | 2019-2021 | |
| Alkermes, INC. | $103.21 | 2020-2025 | Lybalvi, Aristada |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $96.19 | 2019-2021 | |
| Corium, LLC | $75.18 | 2023-2025 | Azstarys |
| Livanova USA, INC. | $53.73 | 2021-2024 | Vns Therapy Symmetry Model 8103 Generator |
| Noven Therapeutics, LLC | $50.67 | 2020-2024 | Xelstrym, Secuado |
| Jazz Pharmaceuticals INC. | $45.07 | 2021 | |
| Tris Pharma INC | $42.52 | 2020-2021 | |
| Bausch Health US, LLC | $39.87 | 2024-2025 | Aplenzin, Wellbutrin |
| Vanda Pharmaceuticals INC. | $38.18 | 2024-2025 | Fanapt |
| Collegium Pharmaceutical, INC. | $37.41 | 2025 | Jornay Pm |
| Neuronetics, INC. | $33.88 | 2019-2021 | |
| Rhodes Pharmaceuticals L.P. | $18.82 | 2019 | |
| Almatica Pharma LLC | $18.58 | 2024 | Loreev Xr |
| Allergan, INC. | $18.14 | 2020 | |
| Acadia Pharmaceuticals INC | $16.65 | 2023 | Nuplazid |
| Vertical Pharmaceuticals, LLC | $15.43 | 2025 | Relexxii |
| Validus Pharmaceuticals LLC | $2.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Cubano listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.